 | Up a level |
Bishop, Michael R., Dickinson, Michael, Purtill, Duncan, Barba, Pere, Santoro, Armando, Hamad, Nada, Kato, Koji, Sureda, Anna, Greil, Richard, Thieblemont, Catherine, Morschhauser, Franck, Janz, Martin, Flinn, Ian W., Rabitsch, Werner, Kwong, Yok Lam, Kersten, Marie Jose, Minnema, Monique C., Holte, Harald, Chan, Esther Hian Li, Martinez-Lopez, Joaquin, Mueller, Antonia M. S., Maziarz, Richard T., McGuirk, Joseph P., Bachy, Emmanuel, Le Gouill, Steven, Dreyling, Martin, Harigae, Hideo, Bond, David A., Andreadis, Charalambos, McSweeney, Peter A., Kharfan-Dabaja, Mohamed A., Newsome, Simon, Degtyarev, Evgeny, Del Corral, Chris, Andreola, Giovanna, Masood, Aisha, Schuster, Stephen J., Jaeger, Ulrich, Borchmann, Peter and Westin, Jason R. (2021). Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study. Blood, 138. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Buecklein, Veit L., Perez-Perez, Ariel, Rejeski, Kai, Iacoboni, Gloria, Jurinovic, Vindi, Holtick, Udo, Penack, Olaf, Kharboutli, Soraya, Blumenberg, Viktoria, Ackermann, Josephine, Froelich, Lisa, Johnson, Grace, Patel, Kedar, Arciola, Brian, Schmidt, Christian, Albanyan, Omar, Goedel, Philipp, Hoster, Eva, Bullinger, Lars, Mackensen, Andreas, Locke, Frederick L., von Bergwelt, Michael, Barba, Pere, Jain, Michael D. and Subklewe, Marion (2022). Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection. Blood, 140. S. 2411 - 2414. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020